Pfizer

Pfizer has introduced Rimegepant ODT for adults who do not respond well to triptans, entering a migraine market nearing $200 million, projected to double by 2030 as India faces rising disease burden

The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Pfizer has pledged to make some medicines available at lower prices for the Medicaid programme and in return gained relief from immediate import tariffs

Pfizer and the White House were deadlocked for months over lowering US drug prices, with Trump demanding quick results from drug executives right from the start of his second term

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with the Trump administration, President Donald Trump said Tuesday, as he promised similar deals will be struck with other drugmakers facing a threat of tariffs. The announcement, which Trump made with Pfizer CEO Albert Bourla at the White House, came as the Republican president has for months sought to lower drug costs. It also came as Washington faced a federal government shutdown at midnight amid a standoff between Democrats and Republicans over health care and its costs. Under the agreement, New York-based Pfizer will charge most-favoured-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations. I can't tell you how big this is," the president said. I think," Bourla said, today we are turning the tide and we are reversing an unfair situation. Trump has been talking for months about the need to lower dru

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.

Here is the complete list of stocks that will trade ex-dividend on July 9, following their announcements of dividend rewards for shareholders

Technical outlook on smallcap stocks - Anand Rathi, Suven Life Sciences, Pfizer, Clean Science and Jindal Saw seem to be favourably placed, and can potentially gain up to 19% from here on.

The US Food and Drug Administration may limit Covid-19 boosters shots to high-risk groups from 2025; Pfizer reviewing proposal as agency seeks new trials, clearer risk labels for younger males

Pfizer's Q4 profit surged to ₹331 crore, aided by a ₹172 crore gain from land sale; board declares ₹165 dividend per share, including special payouts for FY25

Pfizer shares climbed after the company reported a strong set of March quarter results on May 19, 2025.

Q4 FY25 company results today: New India Assurance, NLC India, PI Industries, Borosil, Everest Industries and Gujarat Gas will be among 98 firms to post earnings reports for the Jan-Mar quarter

It reported total revenue of $13.70 billion for the first quarter, compared with analysts' expectations of $13.91 billion, according to LSEG data

According to the company's latest statement, one patient experienced a potential liver injury that may have been caused by the drug

The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the delay by Pfizer, where he worked before joining the British company

China reassures foreign investors amid geopolitical tensions, urging open markets and promising a better business environment at the China Development Forum

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its goals for a subset who have a specific genetic mutation

The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on most goods from Mexico and Canada